appScorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Bharat Parenterals Ltd
BPLPHARMA
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Price
Price Upside
—
Earnings
Earnings Growth
—
Revenue
Rev. Growth
—
Company Profile
Bharat Parenterals Limited is a pharmaceutical company that makes pharmaceutical formulations. Its products include general, beta-lactam, cephalosporins, antiretroviral, and veterinary.
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Recent NewsAll news
Hmm, looks like data is unavailable here. Please come back after some timeRecent EventsAll events
Company Update
Bharat Parenterals Ltd - 541096 - General Announcement About BPL''s Subsidiary Lnnoxel Lifesciences In Regard To Out-Licenses Two Molecules To Leading Generic Pharma Mncs Based Out Of The USA | Download
Bharat Parenterals Ltd - 541096 - General Announcement About BPL''s Subsidiary Lnnoxel Lifesciences In Regard To Out-Licenses Two Molecules To Leading Generic Pharma Mncs Based Out Of The USA | Download
Cash Dividend
Final • Div/Share: ₹ 1
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant